Osta Biotechnologies Inc.
TSX VENTURE : OBI

Osta Biotechnologies Inc.

March 27, 2007 09:10 ET

Osta Appoints Dr. Batist to its Clinical Advisory Board

MONTREAL, QUEBEC--(CCNMatthews - March 27, 2007) -

THE ISSUE OF THIS PRESS RELEASE IS LIMITED TO CANADA ONLY. THIS PRESS RELEASE SHOULD NOT BE ISSUED IN THE UNITED STATES THROUGH U.S. NEWS WIRE AGENCIES.

Osta Biotechnologies Inc. (TSX VENTURE:OBI) is pleased to announce the appointment of Dr. Gerald Batist to its Clinical Advisory Board.

Dr. Batist is a renowned Professor of Oncology and Medicine, Chairman, Department of Oncology, Faculty of Medicine, McGill University, Director, McGill Centre for Translational Research in Cancer, Director, Montreal Centre for Experimental Therapeutics in Cancer and Director of Segal Cancer Centre at the Sir Mortimer B. Davis - Jewish General Hospital. As a recognized authority in cancer research, Dr. Batist has been engaged in basic and translational cancer research for many years. He has expertise in tumor biology, cancer pharmacology, experimental therapeutics, and cancer target discovery. He has published extensively in these areas and has been serving on several scientific panels and research committees. He has held numerous grants and awards, including from the NIH, NCIC, CIHR, FRSQ, NSERC, the Cancer Breast Cancer Research Foundation and Canada Foundation for Innovation.

Dr. Batist received his B.Sc. from Columbia University, New York and M.D. from McGill University. He has previously served as Chief Resident Physician at New England Deaconess Hospital, Harvard Medical School, Boston, Clinical Staff Fellow at National Cancer Institute's (NCI) Navy Oncology Branch and visiting associate at NCI's, Clinical Pharmacology and Surgical Oncology branches in Bethesda, MD, USA.

Dr. Batist stated "I am very excited about the oncology programs under development at Osta and am extremely pleased to join Osta's clinical advisory board".

"It is a great pleasure and honor for us to have one of the world's leading authorities on oncology research and a renowned clinician-scientist like Dr. Batist joining our Clinical Advisory Board. His addition not only strengths our oncology team, but is very timely and synergistic to our new and exciting oncology program. Dr. Batist brings an invaluable and vast knowledge in oncology research as well as solid expertise in the clinical development of chemotherapeutic agents" says Dr. Ajay Gupta, Osta's Chairman & CEO.

About Osta Biotechnologies Inc.

Osta is a biopharmaceutical company listed on the TSX Venture Exchange dedicated to developing novel diagnostics and therapeutics in the areas of Alzheimer's disease, Osteoporosis, Cancer and X-linked hypophosphatemic rickets (XLH).

Certain information in this press release is forward-looking and is subject to numerous risks and uncertainties. By their nature, such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. These risks include actions of Osta's competitors, and those inherent in scientific research and development.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • Osta Biotechnologies Inc.
    Alain Geahchan
    Director of Operations
    (514) 567-5505